Published

Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: European Neuropsychopharmacology
Date: 2026-04-01
Source: Crossref
DOI: 10.1016/j.euroneuro.2025.112746
PubMed: 41546918

Authors

Swieczkowski Damian Kwaśny Aleksander Sadko Krzysztof Cubała Wiesław Jerzy

Watch author

Derived topics and classifications

psilocybin Clinical Trial Clinical Trial

Citation graph

27 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

10.1089/psymed.2023.0007 10.1192/j.eurpsy.2023.2479 10.3389/fpsyg.2022.887255 10.1016/j.nsa.2024.103938 10.1177/00221678221085800 10.1177/02698811251338214 10.1007/7854_2021_298 10.1016/j.euroneuro.2025.11.007 10.1016/j.psychres.2025.116359 10.1016/j.psychres.2023.115531 10.1007/s00213-017-4820-5 10.21037/apm-24-35

Indexed papers citing this DOI

Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols2026-04-01

Related papers

Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)Journal of Clinical Medicine · 2026-08-12 Psychedelic Therapy for DepressionUnknown journal · 2026-08-11 Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot StudyClinicalTrials.gov · 2026-08-10 Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.Nature medicine · 2026-08-06 Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overviewJournal of Psychedelic Studies · 2026-07-13 Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)ClinicalTrials.gov · 2026-07-09 Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility studyBMJ Open · 2026-07-01 Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions.Molecular psychiatry · 2026-06-25